8 November 2021
Yokohama Japan, 8 November 2021: REPROCELL has signed a new agency agreement with Ajinomoto Group for the marketing and sale of StemFit Basic03 GMP and GMP compliant recombinant human bFGF. These clinical-grade products are suitable for cell culture workflows leading to therapeutic applications.
25 October 2021
GLASGOW, October 25, 2021: Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD). Fresh explants of ulcerative colitis and Crohn’s disease tissues will be used to investigate the therapeutic potential of Hoth's HT-003 drugs. All testing will be performed at REPROCELL's Centre for Predictive Drug Discovery.
Hyderabad India – 15 September 2021: Bioserve Biotechnologies India Pvt. Ltd. (a 100% owned subsidiary of REPROCELL Inc) will sponsor a webinar series hosted by the Society of Fetal Medicine in September. The title of the webinar is “Genetic Testing in Fetal Medicine-Navigating the Maze”.
2 September 2021
Yokohama Japan, 02 September 2021: REPROCELL have signed a Strategic Collaboration Agreement with TEXCELL JAPAN, a TEXCELL Group Company, for GMP iPSC - Master Cell Banks (MCB) Manufacturing. The TEXCELL Group (hereinafter “TEXCELL”) is a contract manufacturing organization (CMO) headquartered in France and managed by the holding company SOPARBIOTECH INTERNATIONAL.
Yokohama Japan, 18 August 2021: REPROCELL have signed a Master Service Agreement with TEXCELL JAPAN a TEXCELL Group Company for GMP iPSC - Master Cell Banks (MCB) Manufacturing. The TEXCELL Group (hereinafter “TEXCELL”) is a contract manufacturing organization (CMO) headquartered in France and managed by the holding company Soparbiotech International.
Glasgow, UK: REPROCELL employees, Zara Puckrin and Graeme Macluskie, have published a headline article in the latest issue of European Biopharmaceutical Review (EBR).
Maryland, USA: REPROCELL has opened a new Seed iPSC Manufacture Suite (SiMS) in response to increasing demand for iPSC-derived Master Cell Banks (MCBs).
21 June 2021
Yokohama, Japan: We are pleased to announce that REPROCELL will launch a new testing service of identification for Covid-19 variants, including the Indian (Delta), UK, South African, and Brazilian variants. These have all been identified as Variants of Concern (VOC) by the World Health Organization.
24 May 2021
We are pleased to announce that administrations of Stemchymal, a regenerative medicine product derived from somatic stem cells, have been completed to all enrolled patients in phase II clinical trial for the treatment of spinocerebellar ataxia in Japan. The safety and efficacy of Stemchymal will continue to be investigated during a certain observation period.
Sign up to receive information from REPROCELL about our products, services, applications, promotions, and news (includes a weekly blog update email).